What's Changing: Market Access Challenges with Anti-VEGF The -

Name: What's Changing: Market Access Challenges with Anti-VEGF Therapies - Webcast
Uploaded: 2019-10-01T08:00:00+00:00
Duration: 13 min
Description: The introduction of anti-VEGF agents for the treatment of age-related macular degeneration (AMD), diabetic retinopathy (DR), and retinal vein occlusion (RV

Media formats available:

Details

Presenters

Overview
The introduction of anti-VEGF agents for the treatment of age-related macular degeneration (AMD), diabetic retinopathy (DR), and retinal vein occlusion (RVO), transformed the management of these conditions. While the clinical benefits of these compounds are well documented their use brings up other issues for ophthalmologists, namely, cost. Thus, payers have become more involved in managing the use of these agents, potentially interfering with clinical decision making. This live event brings together thought leaders in the retina field to discuss the challenges they face in obtaining access to anti-VEGF medications for their patients, and how they overcome those challenges.This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.
Learning Objectives
Upon completion of this activity, the participant should be able to:
- Identify and Implement algorithms, decision-making tools, and patient communication approaches that can be used to determine the most appropriate treatment for the patient.
- Identify opportunities to advocate against prior authorizations and step policies and appeal them.
- Identify the potential impact of the Drug Quality and Security Act and opportunities to advocate for continued access to compounded ophthalmologic drugs.
- Describe the impact of the Medicare Access and CHIP Reauthorization Act (MACRA) on ophthalmology and its potential impact on the prescribing of anti-VEGF agents.
Accreditation
ACCREDITATION STATEMENT Evolve Medical Education LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. CREDIT DESIGNATION STATEMENT Evolve Medical Education LLC designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Faculty and Disclosures
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.
Nathan Steinle, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alimera Sciences, Carl Zeiss Meditec, Genentech, Novartis and Regeneron Pharmaceuticals. Speakers Bureau: Alimera Sciences, Genentech, Notal Vision, and Regeneron Pharmaceuticals, Inc. Grant Research Support: Carl Zeiss Meditec, Genentech, and Regeneron Pharmaceuticals. Stock Shareholder: Vertex Surgical Winston Wong, PharmD, has no financial relationships with commercial interests. Sean Goodale, CPA, MBA, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: AAOE, Genentech, Novartis, and Regeneron Pharmaceuticals. Speakers Bureau: Genentech and Regeneron Pharmaceuticals. Editorial Support Disclosures, Erin K. Fletcher, MIT, director of compliance and education, Evolve; Susan Gallagher-Pecha, director of client services and project management, Evolve, have no financial relationships with commercial interests. Jaya Kumar, MD, peer reviewer, has no financial relationships with commercial interests.
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
  Apple Safari for Mac OS and iOS
  Mozilla Firefox for Windows, Mac OS, iOS, and Android
  Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date: 10/01/2019
Expiration Date: 10/31/2020